The largest database of trusted experimental protocols

Ristocetin

Manufactured by Merck Group
Sourced in United States

Ristocetin is a laboratory product manufactured by Merck Group. It is a glycopeptide antibiotic that is used in coagulation assays to evaluate von Willebrand factor (vWF) activity and the diagnosis of von Willebrand disease. The core function of Ristocetin is to induce the aggregation of platelets, which is a key step in the assessment of vWF function.

Automatically generated - may contain errors

9 protocols using ristocetin

1

Platelet Aggregation Assay Reagents

Check if the same lab product or an alternative is used in the 5 most similar protocols
Dimethyl sulfoxide (DMSO), ristocetin (ristomycin monosulfate), ethylenediaminetetraacetic acid disodium salt (EDTA), platelet-activating factor-16 (PAF), acetylsalicylic acid (ASA), 4-methyl-1,2-benzenediol (4-methylcatechol, 4-MC), 9,11-dideoxy-9α,11α-methanoepoxy prostaglandin F2α (U-46619) and ticagrelor were purchased from Sigma (St. Louis, MO, USA). Arachidonic acid (AA), adenosine-5’-diphosphate (ADP) and thrombin receptor agonist peptide-6 (TRAP) were obtained from Roche (Basel, Switzerland). The physiological solution was purchased from B. Braun (Melsungen, Germany), and collagen from Diagnostica, a.s. (Prague, Czech Republic). Vorapaxar was purchased from Selleck Chemicals GmbH (Munich, Germany).
+ Open protocol
+ Expand
2

Platelet Aggregation Assay Methodology

Check if the same lab product or an alternative is used in the 5 most similar protocols
Platelet aggregation was studied according to the densitometric method of Born, as reported [29 (link)]. The following agonists and concentrations were used: Collagen (4 µg/mL) (Mascia Brunelli, Milan, Italy), adenosine diphosphate (5 µM) (Sigma-Aldrich, St Louis, MO, USA), and ristocetin (1.5 and 3.0 mg/mL) (Sigma-Aldrich).
+ Open protocol
+ Expand
3

Platelet Aggregation Assay Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols
Platelet aggregation assay was performed as described previously [22 (link), 23 (link)]. Human platelet suspension was prepared at ~2.5 × 105 per microliter by mixing platelet-rich plasma (PRP) and autologous platelet-poor plasma (PPP) prepared by differential centrifugation from 0.38% citrated blood. After incubation with 10 μg/mL of mAb SZ-123, human IgG, or different concentrations of MHCSZ-123 at 37 °C for 10 min, platelet aggregation was induced by 1.25 mg/mL ristocetin (Sigma) under constant stirring (1000 rpm). Platelet aggregation was measured according to the change in light transmission using a lumiaggregometer (Chrono-log, Havertown, PA, USA).
+ Open protocol
+ Expand
4

Production and Characterization of Anti-VWF Monoclonal Antibodies

Check if the same lab product or an alternative is used in the 5 most similar protocols
Blood donations were from healthy volunteers who provided written informed consent. The pMH3 vector and CHO-S cells were purchased from AmProtein (Hangzhou, China). Restriction enzymes, T4 DNA ligase, and Taq DNA polymerase were obtained from New England BioLabs (Beverly, MA, USA). Rabbit anti-human VWF polyclonal antibody and rabbit anti-human VWF-HRP antibody were purchased from Dako Cytomation (Glostrup, Denmark). Ristocetin, tetramethylbenizidine (TMB), and collagen type III from human placenta were purchased from Sigma (St. Louis, MO, USA). Goat anti-mouse IgG and Goat anti-mouse IgG labeled with horseradish peroxidase (HRP) were purchased from Beckman-Coulter (Brea, CA, USA). SZ-123, a murine anti-human VWF A3 domain mAb (IgG1) was produced by standard hybridoma technology in our laboratory as described previously [22 (link)]. SZ-34, a murine mAb that binds to the VWF A2 domain but does not inhibit its function, was produced by standard hybridoma technology in our laboratory [25 (link)].
+ Open protocol
+ Expand
5

Platelet-binding Ability of Recombinant Leptospiral Proteins

Check if the same lab product or an alternative is used in the 5 most similar protocols
Hu/Ms-platelet-binding ability of rLep-vWA-I or rLep-vWA-II was determined by flow cytometry [27 (link)]. Briefly, the Hu/Ms-platelets (107) were incubated with 2 μg rLep-vWA-I or rLep-vWA-II at 22 °C for 0.5, 1, 2 or 4 h, and then thoroughly washed with 0.01 M phosphate buffered saline (PBS, pH 7.4). Using 1:200 diluted rabbit anti-rLep-vWA-I- or rLep-vWA-II-IgG as the primary antibody and FITC-labeled goat anti-rabbit-IgG (Abcam, USA) as the secondary antibody, the Hu/Ms-platelet-binding percentages of rLep-vWA-I and rLep-vWA-II were detected using a flow cytometer (type FC-500MCL, Beckman Coulter, USA) with 485/538 nm excitation/emission wavelengths. In the detection, 10 μg rHu/rMs-vWF (Abcam) plus 150 μM ristocetin (Sigma), a common cofactor of vWF for binding GPIbα to induce platelet aggregation in vitro [26 (link),28 (link)], and rHlpA, a recombinant hemolysin of L. interrrogans [24 (link)], were used as the controls.
+ Open protocol
+ Expand
6

Murine Platelet Aggregometry Assay

Check if the same lab product or an alternative is used in the 5 most similar protocols
Murine whole blood was collected from the inferior vena cava and mixed with acid-citrate dextrose solution (85 mM trisodium citrate, 71 mM citric acid, and 111mM dextrose) in a 6:1 ratio. After diluting it with an equal volume of 1× DPBS (Invitrogen), the blood was centrifuged at 90×g for 20 min and the platelet-rich plasma (PRP) was collected and centrifuged at 750×g for 10 min in the presence of 50ng/ml prostacyclin. The pelleted platelets were then suspended and washed twice with 1×PBS in the presence of 50ng/ml prostacyclin. After the final wash, platelets were resuspended in 1×PBS buffer to a concentration of 2.0×108/ml. The aggregometry analyses of vWf binding to either wild type or mutant platelets (2×105/ml) under stirring conditions were performed in the presence of 1.5mg/ml ristocetin (Sigma) and 10μg/ml human vWf (Sekisui Diagnostics) with an eight channel Bio/Data PAP-8C aggregometer (Biodata Corporation).
+ Open protocol
+ Expand
7

Platelet Aggregation and Signaling Assays

Check if the same lab product or an alternative is used in the 5 most similar protocols
Ristocetin was purchased from Sigma-Aldrich (Darmstadt, Germany). Recombinant CXCL12, mouse anti-CXCR4 monoclonal antibody, mouse anti-CXCR7 monoclonal antibody, and the soluble CD40 ligand (sCD40L) ELISA kit were purchased from R & D Systems, Inc. (Minneapolis, MN, USA). NSC23766 and Y27632 were purchased from Tocris Bioscience (Bristol, UK) and Calbiochem/Novabiochem Co. (La Jolla, CA, USA), respectively. GAPDH rabbit polyclonal antibody (cat. no. SC-25778) was purchased from Santa Cruz Biotechnology, Inc. (Dallas, TX, USA). Phospho-specific cofilin antibodies were obtained from Cell Signaling Technology, Inc. (Danvers, MA, USA). Rac1 and Rho activation assay kits were purchased from Millipore (Billerica, MA, USA). Other materials and chemicals were obtained from commercial sources. Ristocetin was dissolved in dimethyl sulfoxide. The maximum concentration of dimethyl sulfoxide was 0.1%, which did not affect the platelet aggregation.
Y27632 and NSC23766 were dissolved in dimethyl sulfoxide. The maximum concentration of dimethyl sulfoxide was 0.3%, which did not affect the platelet aggregation, protein detection by Western blotting or ELISA for sCD40L.
+ Open protocol
+ Expand
8

Platelet activation by agonists in mice

Check if the same lab product or an alternative is used in the 5 most similar protocols
Platelet agonist ADP and collagen (equine tendon) were from HELENA laboratories (USA). Ristocetin was from Sigma (R7752, USA). Anti-human GPIbα monoclonal antibody SZ2, VM16d, and AK2 were from GenTex (GTX28822, USA), YO Proteins (656, USA), and Bio-Rad (MCA740T, USA), respectively. Secondary antibody anti-human/mouse CD62P (P-selectin) APC was from Thermo Fisher scientific (17-0626, USA), and FITC-conjugated anti-human PAC-1 was from Biolegend (362803, USA). Peptides of GPIbα fragments were synthesized by GL Biochen (China) Ltd. Recombinant mouse vWF protein was from Creative BioMart (VWF-1432 M, USA), and human vWF protein was from Sino Biological (10973-H08C, USA). C57BL/6J mice, BCLB/C mice, and Wistar rat were from JSJ laboratories (China) and were bred and housed at Putuo animal care facility. Transgenic mice expressing no mouse but only human GPIbα (hTg) were described previously [19 (link)]. Animal experiments were conducted in mice or rats using protocols approved by the IACUC of Putuo Hospital. Six- to eight-week-old mice or rats were used in the study, and investigators were blinded to group allocation during data collection.
+ Open protocol
+ Expand
9

Platelet function assay protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols
ADP, ristocetin and adrenaline were purchased from Sigma (Poole, UK). Arachidonic acid and U46619 were purchased from Cayman Chemical Company (Michigan, USA). The PAR-1 peptide (SFLLRN) was purchased from Severn Biotech (Kidderminster, UK). Collagen was purchased from Takeda (Austria) and luciferin luciferase reagent (Chrono-lume) was purchased from Chrono-log Corporation (Havertown, PA, USA). The reagents were dissolved in phosphate-buffered saline (PBS) at pH 7.4 and stored as frozen aliquots, thawed and diluted in PBS when required and kept on ice. Collagen was stored as a concentrated stock at 1 mg/ml as supplied by the manufacturer at 4°C and diluted with the buffer provided. AR chip, PL chip, CaCl2 containing 1.25 mg/mL of Corn Trypsin Inhibitor (CaCTI) and 3.2% sodium citrate were provided by Quadratech Diagnostics Limited (Epsom, UK). 25 g/ml hirudin blood tubes were purchased from Roche Diagnostics (Munich, Germany). Ticagrelor (10 mM) and Rivaroxaban (10 mM) stock solutions were provided by Leeds Institute of Cardiovascular and metabolic medicine, University of Leeds (Leeds, UK).
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!